

Spongiacidin C, a pyrrole alkaloid from the marine sponge *Stylissa massa*, functions as a USP7 inhibitor

Michitaka Yamaguchi, Mitsue Miyazaki, Matthew P. Kodrasov, Henki Rotinsulu, Fitje Losung, Remy E. P. Mangindaan, Nicole J. de Voogd, Hideyoshi Yokosawa, Benjamin Nicholson, Sachiko Tsukamoto

Downloaded from:

<https://doi.org/10.1016/j.bmcl.2013.04.066>


Article 25fa Dutch Copyright Act (DCA) - End User Rights

This publication is distributed under the terms of Article 25fa of the Dutch Copyright Act (Auteurswet) with consent from the author. Dutch law entitles the maker of a short scientific work funded either wholly or partially by Dutch public funds to make that work publicly available following a reasonable period after the work was first published, provided that reference is made to the source of the first publication of the work.

This publication is distributed under the Naturalis Biodiversity Center 'Taverne implementation' programme. In this programme, research output of Naturalis researchers and collection managers that complies with the legal requirements of Article 25fa of the Dutch Copyright Act is distributed online and free of barriers in the Naturalis institutional repository. Research output is distributed six months after its first online publication in the original published version and with proper attribution to the source of the original publication.

You are permitted to download and use the publication for personal purposes. All rights remain with the author(s) and copyrights owner(s) of this work. Any use of the publication other than authorized under this license or copyright law is prohibited.

If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the department of Collection Information know, stating your reasons. In case of a legitimate complaint, Collection Information will make the material inaccessible. Please contact us through email: collectie.informatie@naturalis.nl. We will contact you as soon as possible.



Spongiacidin C, a pyrrole alkaloid from the marine sponge *Stylissa massa*, functions as a USP7 inhibitor



Michitaka Yamaguchi^a, Mitsue Miyazaki^a, Matthew P. Kodrasov^b, Henki Rotinsulu^c, Fitje Losung^d, Remy E. P. Mangindaan^d, Nicole J. de Voogd^e, Hideyoshi Yokosawa^f, Benjamin Nicholson^b, Sachiko Tsukamoto^{a,*}

^a Department of Natural Medicines, Graduate School of Pharmaceutical Sciences, Kumamoto University, Oe-honmachi 5-1, Kumamoto 862-0973, Japan

^b Division of Research and Development, Progenra, Inc., 277 Great Valley Parkway, Malvern, PA 19355, USA

^c Faculty of Agriculture, Universitas Pembangunan Indonesia, Manado 95361, Indonesia

^d Faculty of Fisheries and Marine Science, Sam Ratulangi University, Kampus Bahu, Manado 95115, Indonesia

^e Netherlands Centre for Biodiversity Naturalis, PO Box 9517, 2300 RA Leiden, The Netherlands

^f School of Pharmacy, Aichi Gakuin University, Chikusa-ku, Nagoya 464-8650, Japan

ARTICLE INFO

Article history:

Received 12 March 2013

Revised 11 April 2013

Accepted 25 April 2013

Available online 3 May 2013

Keywords:

Spongiacidin C
Pyrrole alkaloid
Stylissa massa
USP7 inhibitor

ABSTRACT

USP7, a deubiquitylating enzyme hydrolyzing the isopeptide bond at the C-terminus of ubiquitin, is an emerging cancer target. We isolated spongiacidin C from the marine sponge *Stylissa massa* as the first USP7 inhibitor from a natural source. This compound inhibited USP7 most strongly with an IC₅₀ of 3.8 μM among several USP family members tested.

© 2013 Elsevier Ltd. All rights reserved.

The ubiquitin–proteasome system regulates various cellular events including cell-cycle control, transcription, and signal transduction through protein degradation by the 26S proteasome.^{1,2} In the ubiquitin system, client proteins are polyubiquitylated by the sequential actions of three enzymes: ubiquitin-activating enzyme (E1); ubiquitin-conjugating enzyme (E2); and ubiquitin-protein ligase (E3).¹ This protein ubiquitylation is reversed by deubiquitylating enzymes (DUBs) that cleave the isopeptide bond at the C-terminus of ubiquitin,^{3–5} leading to deconjugation of the ubiquitin chain in client proteins prior to the degradation. Thus, the proteasome-mediated degradation is controlled by the coordinated actions of the ubiquitin system and DUBs. Two proteasome inhibitors, VELCADE® (bortezomib)⁶ and Kyprolis™ (carfilzomib),⁷ were approved for the treatment of multiple myeloma by the FDA in 2003 and 2012, respectively, and the components of the ubiquitin–proteasome system have become attractive targets for the development of anticancer agents.^{8,9} Among inhibitors of the enzymes in the ubiquitin system, E3 inhibitors are expected to be more specific and less toxic drugs than proteasome inhibitors because the respective E3s recognize specific target proteins. In addition,

inhibitors of specific DUBs are also expected to be specific drugs because the respective DUBs show specific intracellular localization, biological roles, and substrate specificities.^{3–5,10} The human genome encodes at least 98 DUBs, and altered DUB functions are related to several diseases including cancer. Among them, USP7 is an emerging oncology target because it stabilizes Hdm2 (human Mdm2), a major E3 for the tumor suppressor protein p53.^{11,12} Hdm2 is auto-ubiquitylated, resulting in its own degradation by the proteasome. USP7 is capable of binding to and deubiquitylating auto-ubiquitylated Hdm2, which leads to stabilization of Hdm2 and consequent degradation of p53. Hence, a USP7 inhibitor stabilizes p53 in cells through degradation of Hdm2, which subsequently results in the suppression of cancer. Several USP7 inhibitors have been developed by screening libraries of synthetic small molecules and by chemical modifications of lead compounds.^{13–17} As an alternative approach, we screened our natural product library composed of marine invertebrate extracts, which are expected to contain structurally diverse and biologically significant metabolites. Here we report the identification of spongiacidin C (**1**) from the marine sponge *Stylissa massa* as the first USP7 inhibitor isolated from a natural source.

The screening of EtOAc- and water-soluble fractions derived from EtOH-extracts of 700 marine invertebrates was performed

* Corresponding author. Tel.: +81 96 371 4380.

E-mail address: sachiko@kumamoto-u.ac.jp (S. Tsukamoto).




Figure 1. Structures of 1–8.

in 96-well plates using recombinant full-length USP7¹⁸ with ubiquitin-Rh110 (LifeSensors, Inc.) as a quenched, fluorescent substrate. After USP7 (0.9 nM) in 80 μ L of 0.2 M Tris–HCl buffer, pH 8.0, containing 20 mM CaCl₂, 0.05% CHAPS, and 2 mM 2-mercaptoethanol was incubated with a test sample (5 μ g/mL) at 25 °C for 30 min, 0.5 μ M ubiquitin-Rh110 in 20 μ L of the buffer was added to the wells, and the mixture was further incubated at 25 °C. Then, the fluorescence intensity due to rhodamine, produced by USP7-catalyzed cleavage of the amide bond between the C-terminal glycine of ubiquitin and rhodamine in ubiquitin-Rh110, was measured within the linear range of the assay on a fluorometric plate reader with excitation and emission wavelengths of 490 and 530 nm, respectively.

One of the hits of this screen was the extract from the marine sponge *Stylissa massa*,¹⁹ which was collected at a depth of 10 m in North Sulawesi, Indonesia, in December 2006 and soaked in EtOH immediately. The extract was concentrated and the residual aqueous layer was partitioned with EtOAc and then *n*-BuOH. Purification from the EtOAc-soluble fraction (3.3 g) by SiO₂ column chromatography (MeOH/CHCl₃) and ODS column chromatography (MeOH/H₂O) followed by ODS HPLC (MeOH/H₂O) afforded spongiacidin C²⁰ (**1**, 0.67 mg) and dibromophakellin²¹ (**2**, 3.6 mg). In addition, purification from the *n*-BuOH-soluble fraction (12.4 g) by ODS column chromatography (MeOH/H₂O) and SiO₂ column chromatography (MeOH/CHCl₃) followed by ODS HPLC (MeOH/H₂O and CH₃CN/H₂O) afforded debromohymenialdisine²² (**3**, 116.6 mg), hymenialdisine²³ (**4**, 8.7 mg), manzacidin A²⁴ (**5**, 6.1 mg), manzacidin B²⁴ (**6**, 3.1 mg), manzacidin C²⁴ (**7**, 2.2 mg), and *N*-methylmanzacidin C²⁵ (**8**, 3.3 mg) (Fig. 1). The compounds were identified based on NMR and MS spectral data.

Among the eight compounds, **1** was the strongest inhibitor (IC₅₀, 3.8 μ M), followed by **3** and **4** (congeners of **1**) (20% inhibition at 20 μ M in both cases), but the others had minimal inhibitory activity. Although the structures of **1**, **3**, and **4** are similar, **1** exhibited a stronger inhibitory effect against USP7 than **3** and **4**, suggesting that the presence of a hydantoin ring in **1** was necessary for the USP7 inhibition instead of an aminoimidazolinone ring in **3** and **4**. Next we examined the inhibitory activity of **1** against USP7 and additional USP family members including the core catalytic domains of USP2, USP8, and USP21,^{17,18} and the core catalytic domain of SENP1 (SUMO-specific peptidase 1),²⁶ with their respective substrates, that is, ubiquitin-EK_L (Ub-CHOP2)¹⁷ for USP7, diubiquitin IQF K4804 (LifeSensors, Inc.) for USP2, ubiquitin-Rh110 for USP8 and USP21, and SUMO3-EK_L (SUMO-CHOP2)¹⁷ for SENP1, according to the methods described previously.^{15–18,27} As shown in Table 1, **1** inhibited USP7 strongly (IC₅₀, 3.8 μ M) and USP21 moderately (IC₅₀, 16.6 μ M), but was inactive against USP2, USP8, or SENP1 over the dose range tested. However, it should be noted that when **1** was tested at concentrations up to 50 μ M in follow-up cellular studies, there was no evidence of growth inhibition against the p53 wild type, USP7 expressing human colorectal cancer cell line HCT-116.²⁸

Table 1
Inhibitory activities of **1** against USP family members

Enzyme	IC ₅₀ ^a (μ M)
USP7	3.8 $\pm$ 1.8 ^b
USP2c ^c	>31.6
USP8c ^c	>31.6
USP21c ^c	16.6 $\pm$ 2.8 ^b
SENP1c ^c	>31.6

^a The mean of three independent experiments.

^b SD.

^c Expressed as the core catalytic domain.

In conclusion, we found that spongiacidin C (**1**), isolated from the marine sponge *Stylissa massa*, is a relatively selective inhibitor of USP7. Due to a lack of cytotoxic activity, additional cellular evaluations of USP7 pharmacodynamic markers such as Hdm2 and p53 were not performed. A recent publication demonstrated that a ubiquitin variant, engineered to bind tightly to USP7, inhibits USP7 selectively (*K_D*, 56 nM).²⁹ Additionally, several USP7 inhibitors have been reported, including HBX 41,108 (IC₅₀, 0.42 μ M),¹³ HBX 19,818 (IC₅₀, 28.1 μ M) and HBX 28,258 (IC₅₀, 22.6 μ M),¹⁴ P5091 (IC₅₀, 4.2 μ M),^{15,16} P22077 (IC₅₀, 7.8 μ M),^{16,17,27} and compound **14** (IC₅₀, 0.42 μ M),¹⁶ all of which were obtained from libraries of synthetic chemicals or by subsequent synthetic modifications. Several natural products with a broad DUB inhibitory profile have been described,³⁰ but to the best of our knowledge, **1** is the first USP7 inhibitor isolated from a natural source and exhibited a potency similar to those of some of the previously described USP7 inhibitors derived from synthetic sources. We are currently studying alternative USP7 inhibitory natural product extracts with the goal of adding to this list in the near future.

Acknowledgments

We are grateful to Dr. H. Kobayashi of the University of Tokyo for collection of the sponge. We thank Mr. James LaRocque and Saket Agarwal for contributing to the DUB activity assessments. This work was financially supported in part by Grants-in-Aid for Scientific Research (Nos. 22310138 and 22406001 to S.T.) from the Ministry of Education, Culture, Sports, Science and Technology of Japan and also by grants from the Naito Foundation, the Astellas Foundation for Research on Metabolic Disorders, and the Uehara Memorial Foundation (S.T.).

References and notes

- Glickman, M. H.; Ciechanover, A. *Physiol. Rev.* **2002**, *82*, 373.
- Finley, D. *Annu. Rev. Biochem.* **2009**, *78*, 477.
- Reyes-Turcu, F. E.; Ventii, K. H.; Wilkinson, K. D. *Annu. Rev. Biochem.* **2009**, *78*, 363.
- Komander, D.; Clague, M. J.; Urbe, S. *Nat. Rev. Mol. Cell Biol.* **2009**, *10*, 550.

5. Fraile, J. M.; Quesada, V.; Rodríguez, D.; Freije, J. M.; López-Otín, C. *Oncogene* **2012**, *31*, 2373.
6. Adams, J. *Drug Discovery Today* **2003**, *8*, 307.
7. Thompson, J. L. *Ann. Pharmacother.* **2013**, *47*, 56.
8. Bedford, L.; Lowe, J.; Dick, L. R.; Mayer, R. J.; Brownell, J. E. *Nat. Rev. Drug Disc.* **2011**, *10*, 29.
9. Cohen, P.; Tcherpakov, M. *Cell* **2010**, *143*, 686.
10. Sowa, M. E.; Bennett, E. J.; Gygi, S. P.; Harper, J. W. *Cell* **2009**, *138*, 389.
11. Colland, F. *Biochem. Soc. Trans.* **2010**, *38*, 137.
12. Nicholson, B.; Suresh Kumar, K. G. *Cell Biochem. Biophys.* **2011**, *60*, 61.
13. Colland, F.; Formstecher, E.; Jacq, X.; Reverdy, C.; Planquette, C.; Conrath, S.; Trouplin, V.; Bianchi, J.; Aushev, V. N.; Camonis, J.; Calabrese, A.; Borg-Capra, C.; Sippl, W.; Collura, V.; Boissy, G.; Rain, J. C.; Guedat, P.; Delansorne, R.; Daviet, L. *Mol. Cancer Ther.* **2009**, *8*, 2286.
14. Reverdy, C.; Conrath, S.; Lopez, R.; Planquette, C.; Atmanene, C.; Collura, V.; Harpon, J.; Battaglia, V.; Vivat, V.; Sippl, W.; Colland, F. *Chem. Biol.* **2012**, *19*, 467.
15. Chauhan, D.; Tian, Z.; Nicholson, B.; Kumar, K. G.; Zhou, B.; Carrasco, R.; McDermott, J. L.; Leach, C. A.; Fulciniti, M.; Kodrasov, M. P.; Weinstock, J.; Kingsbury, W. D.; Hideshima, T.; Shah, P. K.; Minvielle, S.; Altun, M.; Kessler, B. M.; Orlowski, R.; Richardson, P.; Munshi, N.; Anderson, K. C. *Cancer Cell* **2012**, *22*, 345.
16. Weinstock, J.; Wu, J.; Cao, P.; Kingsbury, W. D.; McDermott, J. L.; Kodrasov, M. P.; McKelvey, D. M.; Suresh Kumar, K. G.; Goldenberg, S. J.; Mattern, M. R.; Nicholson, B. *ACS Med. Chem. Lett.* **2012**, *3*, 789.
17. Tian, X.; Isamiddinova, N. S.; Peroutka, R. J.; Goldenberg, S. J.; Mattern, M. R.; Nicholson, B.; Leach, C. *Assay Drug Dev. Technol.* **2011**, *9*, 165.
18. Nicholson, B.; Leach, C. A.; Goldenberg, S. J.; Francis, D. M.; Kodrasov, M. P.; Tian, X.; Shanks, J.; Sterner, D. E.; Bernal, A.; Mattern, M. R.; Wilkinson, K. D.; Butt, T. R. *Protein Sci.* **2008**, *17*, 1035.
19. A voucher specimen (RMNH POR 6183) of *Stylissa massa* has been deposited in the Netherlands Centre for Biodiversity Naturalis, The Netherlands.
20. Inaba, K.; Sato, H.; Tsuda, M.; Kobayashi, J. *J. Nat. Prod.* **1998**, *61*, 693.
21. Sharma, G.; Magdoff-Fairchild, B. *J. Org. Chem.* **1977**, *42*, 411.
22. Groszek, G.; Kantoci, D.; Pettit, G. R. *Liebigs Ann.* **1995**, *4*, 715.
23. (a) Cimino, G.; De Rosa, S.; De Stefano, S.; Mazzarella, L.; Puliti, L.; Sodano, G. *Tetrahedron Lett.* **1982**, *23*, 767; (b) Kitagawa, I.; Kobayashi, M.; Kitanaka, K.; Kido, M.; Kyogoku, Y. *Chem. Pharm. Bull.* **1983**, *31*, 2321.
24. (a) Kobayashi, J.; Kanda, F.; Ishibashi, M.; Shigemori, H. *J. Org. Chem.* **1991**, *56*, 4574; (b) Namba, K.; Shinada, T.; Teramoto, T.; Ohfune, Y. *J. Am. Chem. Soc.* **2000**, *122*, 10708.
25. Tsukamoto, S.; Tane, K.; Ohta, T.; Matsunaga, S.; Fusetani, N.; van Soest, R. W. *M. J. Nat. Prod.* **2001**, *64*, 1576.
26. The cloning, expression, and purification of SENP1 from BL21 (DE3) bacteria was performed using standard molecular biology techniques.
27. Altun, M.; Kramer, H. B.; Willems, L. I.; McDermott, J. L.; Leach, C. A.; Goldenberg, S. J.; Kumar, K. G.; Konietzny, R.; Fischer, R.; Kogan, E.; Mackeen, M. M.; McGouran, J.; Khoronenkova, S. V.; Parsons, J. L.; Dianov, G. L.; Nicholson, B.; Kessler, B. M. *Chem. Biol.* **2011**, *18*, 1401.
28. Cummins, J. M.; Rago, C.; Kohli, M.; Kinzler, K. W.; Lengauer, C.; Vogelstein, B. *Nature* **2004**, *428*, 486. <http://dx.doi.org/10.1038/nature02501>.
29. Zhang, Y.; Zhou, L.; Rouge, L.; Phillips, A. H.; Lam, C.; Liu, P.; Sandoval, W.; Helgason, E.; Murray, J. M.; Wertz, I. E.; Corn, J. E. *Nat. Chem. Biol.* **2013**, *9*, 51.
30. Edelmann, M. J.; Nicholson, B.; Kessler, B. M. *Expert Rev. Mol. Med.* **2011**, *13*, e35.